This preparation, a sterile ophthalmic solution, is used to decrease intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Travoprost and Timolol reduce intraocular pressure (IOP) by complementary mechanisms of action. Travoprost is a prostaglandin analogue which reduces IOP by increasing trabecular outflow and uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane stabilizing) activity. It lowers IOP by decreasing the formation of aqueous humor in the ciliary epithelium.

Use in adults: The dose is one drop of Travast Plus in the conjunctival sac of the affected eye(s) once daily, in the morning or evening. It should be administered at the same time each day.

Paediatric patients: The efficacy and safety of Travast Plus in patients below the age of 18 years have not been established.

No specific interaction was observed with Travast Plus eye drops.

Contraindicated in patients who are hypersensitive to Travoprost, Timolol, or any of the components of this preparation.

No serious ophthalmic or systemic undesirable effects related to Travast Plus were reported. The most frequently reported treatment-related undesirable effect was ocular hyperemia. Other common side effects may include keratitis, anterior chamber flare, eye pain, photophobia, eye swelling, conjunctival hemorrhage, corneal staining, ocular discomfort, reduced visual acuity, visual disturbance, blurred vision, etc.

There are no adequate data from the use of Travoprost in eye drops in pregnant women. Travast Plus should not be used during pregnancy unless clearly necessary. It is unknown whether Travoprost from eye drops is excreted in human breast milk. Timolol is excreted in breast milk. The use of Travast Plus by breastfeeding women is not recommended.

Like other topically applied ophthalmic agents, Travoprost and Timolol are absorbed systemically. Due to the beta-adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta-adrenergic blocking agents may occur.

In case of overdose with Travast Plus, treatment should be symptomatic.

Drugs for miotics and glaucoma

Store in a cool, dry place, away from heat and direct light. Keep out of the reach of children. Do not use more than 4 weeks after opening the bottle.